Compare GKOS & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | EXLS |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.9B |
| IPO Year | 2015 | 2006 |
| Metric | GKOS | EXLS |
|---|---|---|
| Price | $113.41 | $42.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $127.71 | $54.50 |
| AVG Volume (30 Days) | 641.9K | ★ 1.2M |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.94 |
| EPS | N/A | ★ 1.48 |
| Revenue | $469,820,000.00 | ★ $2,026,490,000.00 |
| Revenue This Year | $31.15 | $15.32 |
| Revenue Next Year | $24.15 | $11.27 |
| P/E Ratio | ★ N/A | $28.84 |
| Revenue Growth | ★ 30.38 | 14.43 |
| 52 Week Low | $73.16 | $37.30 |
| 52 Week High | $163.71 | $52.43 |
| Indicator | GKOS | EXLS |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 58.63 |
| Support Level | $109.07 | $40.71 |
| Resistance Level | $115.00 | $43.17 |
| Average True Range (ATR) | 2.76 | 0.70 |
| MACD | -0.95 | -0.09 |
| Stochastic Oscillator | 44.01 | 65.25 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.